BNP Paribas Financial Markets’s Recursion Pharmaceuticals RXRX Stock Holding History

BNP Paribas Financial Markets’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$294K	Sell	80,085 -74,016	-48%	-$246K	﹤0.01%	4048
2026 Q1	$473K	Sell	154,101 -930,097	-86%	-$3.59M	﹤0.01%	3622
2025 Q4	$4.43M	Buy	1,084,198 +971,073	+858%	+$4.81M	﹤0.01%	2126
2025 Q3	$552K	Sell	113,125 -1,670	-1%	-$8.77K	﹤0.01%	3492
2025 Q2	$581K	Buy	114,795 +96,360	+523%	+$473K	﹤0.01%	3236
2025 Q1	$97.5K	Sell	18,435 -16,069	-47%	-$117K	﹤0.01%	4043
2024 Q4	$233K	Buy	+34,504	New	+$232K	﹤0.01%	3777
2022 Q4	–	Sell	-107,034	Closed	-$1.14M	–	4512
2022 Q3	$1.14M	Buy	+107,034	New	+$1.08M	﹤0.01%	2380

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

BNP Paribas Financial Markets's RXRX Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Recursion Pharmaceuticals (RXRX) stake by 48% in Q2 2026, selling an estimated $246K and leaving 80,085 shares worth $294K. The position accounts for ﹤0.01% of the portfolio, ranked #4048.

BNP Paribas Financial Markets first reported a position in RXRX in Q3 2022 and has held it in 8 quarters since. The position peaked at $4.43M in Q4 2025. 320 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

BNP Paribas Financial Markets held 80,085 shares of Recursion Pharmaceuticals worth $294K as of Q2 2026.
BNP Paribas Financial Markets sold 74,016 Recursion Pharmaceuticals shares in Q2 2026, an estimated $246K.
Recursion Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4048 holding.
BNP Paribas Financial Markets first reported a position in Recursion Pharmaceuticals in Q3 2022 and has held it in 8 quarters since.
BNP Paribas Financial Markets's Recursion Pharmaceuticals position peaked at $4.43M in Q4 2025.
320 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.